Patents by Inventor Jaekyoung Son

Jaekyoung Son has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
    Patent number: 10837015
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 17, 2020
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • COMPOSITION FOR PREVENTING OR TREATING EGFR-MUTANT NON-SMALL CELL LUNG CANCER
    Publication number: 20200121645
    Abstract: Disclosed is a composition and method for preventing, ameliorating or treating an EGFR-mutant non-small cell lung cancer including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The composition significantly reduces the level of EGFR in EGFR-mutant non-small cell lung cancer cells, inducing apoptosis. Therefore, the composition is suitable for preventing, ameliorating or treating non-small cell lung cancers in subjects in need thereof. Particularly, the composition is effective in treating and preventing non-small cell lung cancers, which are difficult to effectively treat and prevent with gefitinib or erlotinib. Also disclosed is a composition and method for inhibiting the resistance of a non-small cell lung cancer to an EGFR tyrosine kinase inhibitor including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The inhibitory composition effectively overcomes resistance to EGFR tyrosine kinase inhibitors.
    Type: Application
    Filed: February 13, 2019
    Publication date: April 23, 2020
    Applicants: THE ASAN FOUNDATION, University of Ulsan Foundation For Industry Cooperation
    Inventors: Jaekyoung SON, Jin Kyung RHO, Jae Cheol LEE
  • TARGETING THE GLUTAMINE TO PYRUVATE PATHWAY FOR TREATMENT OF ONCOGENIC KRAS-ASSOCIATED CANCER
    Publication number: 20190136238
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Application
    Filed: October 12, 2018
    Publication date: May 9, 2019
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
    Patent number: 10138479
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: November 27, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, Inc.
    Inventors: Alec Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis
  • TARGETING THE GLUTAMINE TO PYRUVATE PATHWAY FOR TREATMENT OF ONCOGENIC KRAS-ASSOCIATED CANCER
    Publication number: 20150110773
    Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.
    Type: Application
    Filed: May 23, 2013
    Publication date: April 23, 2015
    Inventors: Alec C. Kimmelman, Jaekyoung Son, Lewis Cantley, Costas A. Lyssiotis